New research from the University of East Anglia (UK) reveals the hidden struggles experienced by the brothers and sisters of people with Prader–Willi syndrome.

Please provide your email address to receive an email when new articles are posted on . Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is characterized by insatiable hunger. The Food and Drug Administration approved a ...

Prader-Willi syndrome is a genetic disorder caused by changes to chromosome 15. It affects growth, behavior, and learning and requires continual management to avoid potentially life threatening ...

Tania Markovic, MBBS PhD FRACP Jennifer L. Miller, MD Elizabeth Roof, H.S.P., M.A. Theresa V. Strong, PhD On November 6, 2025, the Company held a KOL event to announce the initiation of its PWS ...

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized cutting-edge findings on Prader-Willi syndrome (PWS), revealing how this complex ...

The FDA approved extended-release diazoxide choline (Vykat XR) to treat the intense persistent sensation of hunger in patients 4 years of age and older with Prader-Willi syndrome, maker Soleno ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP ...